BPG is committed to discovery and dissemination of knowledge
Articles in Press
10/16/2026 9:06:38 AM | Browse: 10 | Download: 0
| Category |
Transplantation |
| Manuscript Type |
Minireviews |
| Article Title |
Liver transplantation for hepatocellular carcinoma: Mechanisms, risk stratification, and evolving treatment landscape
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xue-Lin Xiang, Yi-Chi Wu, Zi-Jie Zhang, Xiang-Kun Zhan, Ying Tong, June-Kong Yong, Yi Zhou, Hao Feng and Qiang Xia |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shanghai Science and Technology Development Foundation (Outstanding academic leader) |
No. 23XD1423100 |
| National Natural Science Foundation of China |
No. 82672320 |
|
| Corresponding Author |
Hao Feng, Associate Research Scientist, Deputy Director, MD, PhD, Principal Investigator, Department of Liver Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Institute of Transplantation, Shanghai Engineering Research Center of Transplantation and Immunology, No. 160 Pujian Road, Shanghai 200127, China. surgeonfeng@live.com |
| Key Words |
Liver transplantation; Hepatocellular carcinoma; Recurrence; Multimodality therapy; Transplant oncology; Risk stratification |
| Core Tip |
Post-transplant hepatocellular carcinomarecurrence occurs in 8%-20% of recipients, mainly within 2 years. Key drivers include immunosuppression, tumor biology, and ischemia-reperfusion injury. Risk factors are beyond Milan criteria, microvascular invasion, and high alpha-fetoprotein. Surveillance uses imaging and alpha-fetoprotein, with circulating cell-free DNA-minimal residual diseaseenabling earlier detection. Oligorecurrence benefits from resection or ablation. Advanced disease is treated with tyrosine kinase inhibitors, while immune checkpoint inhibitors risk rejection. Adjuvant lenvatinib improves recurrence-free survival in high-risk patients. artificial intelligence-based models enhance prediction, but evidence remains largely retrospective, requiring prospective trials. |
| Citation |
Xiang XL, Wu YC, Zhang ZJ, Zhan XK, Tong Y, Yong JK, Zhou Y, Feng H, Xia Q. Liver transplantation for hepatocellular carcinoma: Mechanisms, risk stratification, and evolving treatment landscape. World J Hepatol 2026; In press
|
| PDF |
122559-in-press.pdf
|
 |
Received |
|
2026-04-23 06:13 |
|
Peer-Review Started |
|
2026-04-23 06:13 |
|
First Decision by Editorial Office Director |
|
2026-05-07 12:25 |
|
Return for Revision |
|
2026-05-07 12:25 |
|
Revised |
|
2026-06-01 12:49 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-10-16 03:39 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-10-16 09:06 |
|
Articles in Press |
|
2026-10-16 09:06 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
